Baricitinib Provides Significant Hair Regrowth in Adolescents with Severe Alopecia Areata: 52-Week Efficacy and Safety Results from a Phase 3 Randomized, Controlled Trial

    November 2025 in “ SKIN The Journal of Cutaneous Medicine ”
    Brittany Craiglow, Lisa Arkin, David Saceda-Corralo … Ulrike Blume-Peytavi
    Studysummary This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on skin.dermsquared.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Psychosocial Impact of Alopecia Areata in Pediatric and Adolescent Populations: A Systematic Review Journal of Paediatrics and Child Health · 2024
    2. Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2 Journal of the European Academy of Dermatology and Venereology · 2024